Skip to main content
. 2019 Sep 2;11(10):e9930. doi: 10.15252/emmm.201809930

Figure 5. JQ1/Salinomycin combination decreases the bCSC population in patient‐derived xenografts.

Figure 5

  • A
    Schematic representation of the in vivo experimental design.
  • B
    Effect of JQ1 and salinomycin treatment on the tumor growth of CRCM434 (n = 10) (see Fig EV4A and E for CRCM404 and CRCM494). The gray area corresponds to the period of drug treatments. Data represent mean ± SD.
  • C–E
    Quantification of the proportion of residual ALDHbr cells in treated PDX normalized to the proportion of ALDHbr cells in the vehicle‐treated tumors, measured by flow cytometry. Statistical test used is Student's t‐test. Data represent mean ± SD (n = 10).
  • F–I
    Reimplantation assay (CRCM434). Two‐week treated PDXs were reimplanted, in serial dilutions, into new recipient mice, and tumor growth was monitored (F, see Fig EV4 for CRCM404 and CRCM494). Each curve represents the growth kinetic from one individual injection. (G–I) Bar plots display bCSC frequency calculated using an extreme limiting dilution analysis (ELDA). Results are expressed as the estimated number of bCSCs for 10,000 tumor cells. Statistical test used is pairwise chi‐square test.
  • J–L
    Effect of JQ1 and salinomycin treatments on the metastasis formation of CRCM404 and CRCM434. Metastasis formation was monitored using bioluminescence imaging in the treated mice livers and lungs (J). Quantification of the normalized photon flux revealed a statistically significant decrease in metastasis formation in Sal/JQ1‐treated mice compared to the control mice (K, CRCM434, P = 0.04; L, CRCM404, P = 0.02). Statistical test used is a Wilcoxon test. Data represent mean ± SD (n = 10).